Advertisement

International Journal of Hematology

, Volume 76, Issue 5, pp 460–464 | Cite as

Absence of Clinical Prognostic Value of Vascular Endothelial Growth Factor and Microvessel Density in Multiple Myeloma

  • Jung-Hye Choi
  • Myung-Ju Ahn
  • Se-Jin Jang
  • Chan-Kum Park
  • Yong-Wook Park
  • Ho-Suk Oh
  • Young-Yuel Lee
  • Il-Young Choi
  • In-Soon Kim
Case Report

Abstract

Vascular endothelial growth factor (VEGF) is considered a potent stimulator of angiogenesis. In multiple myeloma (MM), it has been reported that bone marrow angiogenesis parallels tumor progression and correlates with a poor prognosis. To investigate the role of angiogenesis in MM, we investigated VEGF expression and microvessel density (MVD) in the bone marrow of 75 MM patients by immunohistochemical methods. VEGF expression was observed in 87.3% (62 of 71) of patients. MVD was 69.42 ± 9.67 (mean ± SE) compared with the normal control values of 26.81 ± 2.85. MVD values were 73.98 ± 11.27 and 36.04 ± 6.99 in the VEGF-positive and VEGF-negative groups, respectively. The MVD of patients in the VEGF-positive group was significantly higher than in the VEGF-negative group (P = .045). However, there were no significant differences in various clinical parameters, such as age, sex, hemoglobin, platelet count, serum levels of albumin, calcium, creatinine, and β2-microglobulin, and bone marrow plasma cell percentage, between the VEGF-positive and VEGF-negative groups. Multivariate analysis revealed that age, hemoglobin, platelet count, serum levels of albumin and creatinine, and bone marrow plasma cell percentage were correlated with overall survival, whereas VEGF expression or MVD was not. In conclusion, our results suggest that VEGF is highly expressed and that MVD is increased in MM, indicating that angiogenesis may play a role in MM. Although MVD in the bone marrow of the VEGF-positive group is significantly higher compared with the VEGF-negative group (P = .045), VEGF is not correlated with overall survival. Further studies that include other angiogenic factors are needed to determine the functional role of angiogenesis in MM. Int J Hematol. 2002;76:460-464.

Key words

Multiple myeloma Vascular endothelial growth factor Microvessel density 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Folkman J. Seminars in medicine of the Beth Israel Hospital Boston: clinical applications of research on angiogenesis.N Engl J Med. 1995;333:1757–1763.CrossRefGoogle Scholar
  2. 2.
    Folkman J. New perspectives in clinical oncology from angiogene- sis research.Eur J Cancer. 1996;14:2534–2539.CrossRefGoogle Scholar
  3. 3.
    Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma.N Engl J Med. 1991;324:1–8.CrossRefGoogle Scholar
  4. 4.
    Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.Am J Pathol. 1993;143:401–409.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Giatromanlaki A, Koukourakis M, O’Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer.J Pathol. 1996;179:80–88.CrossRefGoogle Scholar
  6. 6.
    Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer.J Pathol. 1995;177:57–63.CrossRefGoogle Scholar
  7. 7.
    Meiter D, Crawford SE, Rademaker AW, Cohn S. Tumor angiogen- esis correlates with metastatic disease, n-myc amplification, and poor outcome in human neuroblastoma.J Clin Oncol. 1996;14: 405–414.CrossRefGoogle Scholar
  8. 8.
    Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angio- genic cytokine. In: Goldberg ID, and Rosen EM, eds.Regulation of Angiogenesis. Basel, Switzerland: Birkhauser Verlag; 1997:233–269.CrossRefGoogle Scholar
  9. 9.
    Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries.Cancer Res. 1993;54:276–280.Google Scholar
  10. 10.
    Ferrara N, Houck KA, Jakeman LB, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins.Endocr Rev. 1992;13:18–32.CrossRefGoogle Scholar
  11. 11.
    Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as prognostic indicator and the association with vascular endothelial growth factor expression.Breast Cancer Res Treat. 1995;36:193–204.CrossRefGoogle Scholar
  12. 12.
    Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.Cancer. 1996;77:858–863.CrossRefGoogle Scholar
  13. 13.
    Tanigawa N, Amaya H, Matsumura M, Shimonatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.J Clin Oncol. 1997;15:826–832.CrossRefGoogle Scholar
  14. 14.
    Vacca A, Ribatti D, Presta M, et al. Bone marrow neovasculariza- tion, plasma cell angiogenic potential, and matrix metallopro- teinase-2 secretion parallel progression of human multiple myeloma.Blood. 1999;93:3064–3073.PubMedGoogle Scholar
  15. 15.
    Perez-Atayde A, Sallan SE, Tedrow U, Connors S, Allred E, Folk- man J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.Am J Pathol. 1997; 150:815–821.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Ahn MJ, Park CK, Choi JH, et al. Clinical significance of microves- sel density in multiple myeloma patients.J Korean Med Sci. 2001; 16:45–50.CrossRefGoogle Scholar
  17. 17.
    Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia, and monoclonal gammopathies. In: Hoffbrand AV, Brain MC, Hirsh J, eds.Recent Advances in Hematology. New York, NY: Churchill Livingstone; 1977:243–261.Google Scholar
  18. 18.
    Ribatti D, Vacca RD, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lym- phoma. An immunohistochemical and ultrastructural study.Eur J Haematol. 1996;56:45–53.CrossRefGoogle Scholar
  19. 19.
    Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma.Br J Haematol. 1994;87: 503–508.CrossRefGoogle Scholar
  20. 20.
    Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.Blood. 2000;95:2630–2636.PubMedGoogle Scholar
  21. 21.
    Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.Haematologica. 2000;85:800–805.PubMedGoogle Scholar
  22. 22.
    Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.Blood. 2001;98:428–435.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Jung-Hye Choi
    • 1
  • Myung-Ju Ahn
    • 1
  • Se-Jin Jang
    • 2
  • Chan-Kum Park
    • 2
  • Yong-Wook Park
    • 2
  • Ho-Suk Oh
    • 1
  • Young-Yuel Lee
    • 1
  • Il-Young Choi
    • 1
  • In-Soon Kim
    • 1
  1. 1.Departments of Internal Medicine and bPathologyCollege of Medicine,Hanyang UniversitySeoulKorea
  2. 2.Department of Internal MedicineHanyang UniversitySeoulKorea

Personalised recommendations